Total Synthesis of Human Hepcidin through Regioselective Disulfide-Bond Formation by using the Safety-Catch Cysteine Protecting Group 4,4′-Dimethylsulfinylbenzhydryl

Angewandte Chemie International Edition 53, 2931 (2014).

Blockade of Kv1.3 channels ameliorates radiation-induced brain injury

Neuro Oncol. 10.1074/jbc. M113.517037 (2014).

A Potent and Kv1.3-Selective Analogue of the Scorpion Toxin HsTX1 as a Potential Therapeutic for Autoimmune Diseases

Scientific Reports, 4, 4509 DOI: 10.1038/srep04509 (2014).

A Potent and Selective Peptide Blocker of the Kv1.3 Channel: Prediction from Free-Energy Simulations and Experimental Confirmation

PLoS One. 2013 Nov 7; 8(11):e78712. doi: 10.1371/journal.pone.0078712.

Blocking KCa3.1 Channels Increases Tumor Cell Killing by a Subpopulation of Human Natural Killer Lymphocyte

PLoS One. 2013 Oct 11; 8(10):e76740. doi: 10.1371/journal.pone.0076740.

99mTc-Galacto-RGD2: A Novel 99mTc-Labeled Cyclic RGD Peptide Dimer Useful for Tumor Imaging

Mol. Pharmaceutics 2013 Oct (9), pp 3304–3314 doi: 10.1021/mp400085d.

A C-terminally amidated analogue of ShK is a potent and selective blocker of the voltage-gated potassium channel Kv1.3

FEBS Lett. 2012 Nov 16; 586(22):3996-4001. doi: 10.1016/j.febslet.2012.09.038.

Expression and isotopic labelling of the potassium channel blocker ShK toxin as a thioredoxin fusion protein in bacteria

Toxicon. 2012 Oct; 60(5):840-50. doi: 10.1016/j.toxicon.2012.05.017.

Durable pharmacological responses from the peptide ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease

J Pharmacol Exp Ther. 2012 Sep; 342(3):642-53. doi: 10.1124/jpet.112.191890.

Development of a sea anemone toxin as an immunomodulator for therapy of autoimmune disease

Toxicon. 2012 Mar 15; 59(4):529-46. doi: 10.1016/j.toxicon.2011.07.016.